Juno Therapeutics, Inc. (JUNO) Position Raised by Aperio Group LLC
Aperio Group LLC boosted its position in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 11.9% during the second quarter, Holdings Channel reports. The fund owned 28,360 shares of the biopharmaceutical company’s stock after buying an additional 3,024 shares during the period. Aperio Group LLC’s holdings in Juno Therapeutics were worth $848,000 as of its most recent filing with the SEC.
A number of other large investors have also recently made changes to their positions in the stock. Karp Capital Management Corp purchased a new stake in shares of Juno Therapeutics during the first quarter worth approximately $562,000. UBS Asset Management Americas Inc. increased its stake in shares of Juno Therapeutics by 76.4% in the first quarter. UBS Asset Management Americas Inc. now owns 29,900 shares of the biopharmaceutical company’s stock worth $663,000 after buying an additional 12,947 shares during the last quarter. Pictet Asset Management Ltd. increased its stake in shares of Juno Therapeutics by 14.0% in the first quarter. Pictet Asset Management Ltd. now owns 384,745 shares of the biopharmaceutical company’s stock worth $8,538,000 after buying an additional 47,267 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of Juno Therapeutics by 40.1% in the first quarter. BNP Paribas Arbitrage SA now owns 28,481 shares of the biopharmaceutical company’s stock worth $632,000 after buying an additional 8,150 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Juno Therapeutics by 2.8% in the first quarter. Bank of New York Mellon Corp now owns 262,801 shares of the biopharmaceutical company’s stock worth $5,832,000 after buying an additional 7,165 shares during the last quarter. Hedge funds and other institutional investors own 65.03% of the company’s stock.
Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) traded down 0.26% on Friday, hitting $26.99. The company had a trading volume of 788,677 shares. The company has a 50-day moving average of $28.75 and a 200 day moving average of $24.87. Juno Therapeutics, Inc. has a 12 month low of $17.52 and a 12 month high of $34.35. The stock’s market cap is $2.83 billion.
Juno Therapeutics (NASDAQ:JUNO) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.72) by $0.24. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The business had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million. During the same period in the prior year, the company earned ($0.64) earnings per share. The firm’s revenue for the quarter was down 22.8% on a year-over-year basis. Analysts anticipate that Juno Therapeutics, Inc. will post ($3.13) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.watchlistnews.com/juno-therapeutics-inc-juno-position-raised-by-aperio-group-llc/1508629.html.
JUNO has been the subject of a number of research reports. Vetr downgraded shares of Juno Therapeutics from a “hold” rating to a “sell” rating and set a $28.85 price target for the company. in a research report on Monday, July 24th. Morgan Stanley lifted their price target on shares of Juno Therapeutics from $26.00 to $27.00 and gave the company an “equal weight” rating in a research report on Monday, August 7th. BidaskClub upgraded shares of Juno Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, June 27th. Finally, Zacks Investment Research downgraded shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $30.63.
In related news, Director Richard Klausner sold 12,000 shares of the stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $30.34, for a total transaction of $364,080.00. Following the completion of the sale, the director now directly owns 788,985 shares of the company’s stock, valued at $23,937,804.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Anthony B. Evnin bought 9,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 20th. The shares were acquired at an average cost of $24.40 per share, with a total value of $219,600.00. Following the completion of the purchase, the director now owns 66,301 shares of the company’s stock, valued at $1,617,744.40. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 8,053,500 shares of company stock valued at $217,594,440. Company insiders own 15.26% of the company’s stock.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Want to see what other hedge funds are holding JUNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juno Therapeutics, Inc. (NASDAQ:JUNO).
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.